Jazz halts sleep disorder med trial over 'visual disturbances' and CV effects

Jazz Pharmaceuticals is pressing pause on a phase 1 sleep disorder med due to adverse events despite one executive saying that it “achieved proof of concept.”

The comments were relayed by Chief Medical Officer Kelvin Tan at a conference hosted by Evercore ISI on Tuesday and poured cold water on the near-term prospects of the asset recently licensed from Sumitomo Pharma.